Protective role of oral antioxidant supplementation in ocular surface of diabetic patients

British Journal of Ophthalmology

Volumn 86, Issue 12, 2002, Pages 1369-1373

  Peponis, V ^a,b   Papathanasiou, M ^a   Kapranou, A ^a   Magkou, C ^b   Tyligada, A ^b   Melidonis, A ^a   Droso, T ^c   Sitaras, Nikolaos M ^b  

^a 2nd Department of Internal Medicine   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c IASO GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; FREE RADICAL; NITRIC OXIDE; NITRITE;

ADULT; ARTICLE; CELL DENSITY; CONJUNCTIVA EPITHELIUM; CYTOLOGY; DIABETES MELLITUS; EYE PROTECTION; FEMALE; GOBLET CELL; HUMAN; LACRIMAL FLUID; MAJOR CLINICAL STUDY; MALE; METABOLITE; OXIDATIVE STRESS; PHOTOMETRY; PRIORITY JOURNAL; SCHIRMER TEST; SQUAMOUS CELL METAPLASIA; VITAMIN SUPPLEMENTATION;

ADMINISTRATION, ORAL; AGED; ASCORBIC ACID; CONJUNCTIVA; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; METAPLASIA; MIDDLE AGED; NITRIC OXIDE; NITRITES; TEARS; VITAMIN E;

EID: 0036896189     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.86.12.1369     Document Type: Article

References (57)

1. Schultz RO, Van Horn DL, Peters MA, et al. Diabetic keratopathy. Trans Am Ophthalmol Sac 1981;79:180-99.
2. Goebbles M. Tear secretion and tear film function in insulin dependent diabetics. Br J Ophthalmol 2000;84:19-21.
3. Knight JA. Reactive oxygen species and the neurodegenerative disorders. Ann Clin Lab Sci 1997;27:11-25.
4. Rose RC, Richer SP, Bode AM. Ocular oxidants and antioxidant protection. Proc Sac Exp Biol Med 1998;217:397-407.
5. Will JC, Byers T. Does diabetes mellitus increase the requirement for vitamin C? Nutrition Rev 1996;54:193-202.
6. Becquet F, Courtois Y, Goureau O. Nitric oxide in the eye: Multifaceted roles and diverse outcomes. Surv Ophthalmol 1997;42:71-82.
7. Goldstein I, Ostwald P, Roth S. Minireview. Nitric oxide: A review of its role in retinal function and disease. Vis Res 1996;36:2979-94.
8. Schmetterer L, Polak K. Role of nitric oxide in the control of ocular blood flow. Prog Retin Eye Res 2001;20:823-47.
9. Rösen P, Nawroth PP, King G, et al. The role of oxidative stress in the onset and progression of diabetes and its complications: A summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metabol Res Rev 2001;17:189-212.
10. Cosentino F, Hishikawa K, Katusic ZS, et al. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 1997;96:25-8.
11. Packer L. Vitamin C and redox cycling antioxidants. In: Packer L, Fuchs J, eds. Vitamin C in Health and Disease. New York: Marcel Dekker, 1997:95-121.
12. Rolando M. Tear mucus ferning test in normal and keratoconjunctivitis sicca eyes. Chibert Int J Ophthalmol 1984;2:32-41.
13. Nelson DJ. Cellulose acetate impressions of the ocular surface. Dry eye states. Arch Ophthalmol 1983;101:1869-72.
14. Rajas MV, Rodriguez MT, Blanco JA, et al. Impression cytology in patients with keratoconjuctivitis sicca. Cytopathology 1993;4:347-55.
15. Green LC, Warner DA, Glogowski J, et al. Analysis of nitrate, nitrite and (15N) nitrate in biological fluids. Anal Biochem 1982;126:131-8.
16. The DCCT Research Group. The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: The Diabetes Control and Complications Trial. N Engl J Med 1993;329:977-86.
17. Giugliano D, Cerriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996;19:257-67.
18. Baynes JW, Thorpe SR. The role of oxidative stress in diabetic complications. Curr Opin Endocrinol 1997;3:277-84.
19. Brownlee M. Advanced protein glycosylation in diabetes and aging. Ann Rev Med. 1996;46:223-34.
20. Vlassara H. Recent progress in advanced glycation end products and diabetic complications. Diabetes 1997;46(Suppl 2):S19-25.
21. Hotta N. New approaches for treatment in diabetes: Aldose reductase inhibitors. Blamed Pharmacother 1995;49:232-42.
22. +, free radical and vascular dysfunction in early diabetes meJlitus. Diabetologia 1997;40(Suppl 2):S115-17.
23. Cameron NE, Cotter MA. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes 1997;46 (Suppl 2):S31-7.
24. Lyons TJ, Jenkins AJ. Glycation, oxidation and lipoxidation in the development of the complications of diabetes: A carbonyl stress hypothesis. Diabetes Rev 1997;5:365-91.
25. Witztum JL. Role of modified lipoproteins in diabetic macroangiopathy. Diabetes 1997;46 (Suppl 2):S112-14.
26. Ishii H, Daissuke K, King GL. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J Mol Med 1998;76:21-31.
27. Pfeiffer A, Schatz H. Diabetic microvascular complications and growth factors. Exp Clin Endocrinol Diabetes 1994;103:7-14.
28. Sharma K, Ziyadeh FN. Biochemical events and cytokine interactions linking glucose metabolism to the development of diabetic nephropathy. Sem Nephrol 1997;17:80-92.
29. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications. A new perspective on an old paradigm. Diabetes 1999;48:1-9.
30. Halliwell B. Free radicals, antioxidants and human disease: Curiosity, cause or consequence. Lancet 1994;344:721-4.
31. Hunt JV. Ascorbic acid and diabetes mellitus. In: Harris RJ, ed. Subcellular Biochemistry. Vol 25. Ascorbic Acid: Biochemistry and Biomedical Cell Biology. New York: Plennum Press, 1996:369-405.
32. Jennings PE, Chirico S, Jones AF, et al. Vitamin C metabolites and microangiopathy in diabetes mellitus. Diabetes Res 1987;6:151-4.
33. Sam S, Basu D, Mukherjee S, et al. Ascorbic acid metabolism in diabetes mellitus. Metabolism 1981;30:572-7.
34. Welch RW, Bergsten P, Butler JD, et al. Ascorbic acid accumulation and transport in human fibroblasts. Biochem J 1993;294:505-10.
35. Karpen C, Cataland S, Orisio TM, et al. Interaction of platelet vitamin E and thromboxane synthesis in type 1 diabetes mellitus. Diabetes 1984;33:239-43.
36. Florence TM. The role of free radicals in disease. Aust NZ J Ophthalmol 1995;23:3-7.
37. Chiou SH, Chang CJ, Chou CK, et al. Increased nitric oxide levels in aqueous humor of diabetic patients with neovascular glaucoma. Diabetes Care 1999;22:861-2.
38. Biswas SK, Bhelwa AP, Upadhyay AU, et al. Status of nitric oxide free radicals in diabetic neutrophils: Effect of diabetic serum factor on the generation of these species in normal neutrophils and their relation to lysosomal degranulation. Indian J Biochem Biophys 1993;30:293-6.
39. Wu G. Nitric oxide synthesis and the effect of aminoguanidine and NG-monomethyl- L-arginine on the onset of diabetes in the spontaneously diabetic BB rat. Diabetes 1995;44:360-4.
40. Honing MLH, Morrison PJ, Banga JD, et al. Nitric oxide availability in diabetes mellitus. Diabetes Metab Rev 1998;14:241-9.
41. Baeuerle PA, Henkel T. Function and activation of NF-kB in the immune system. Annu Rev Immunol 1994;12:141-79.
42. McCann SM, Licinio M, Wang L, et al. The nitric oxide hypothesis of aging. Exp Gerontol 1998;33:813-26.
43. Allen JB, Keng T, Privalle CH. Nitric oxide and peroxynitrite production in ocular inflammation. Environ Health Perspect 1998;106 (Suppl 5):1145-9.
44. Yilmaz G, Esser P, Kociek N, et al. Elevated vitreous nitric oxide levels in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2000;130:87-90.
45. Patel S, Farrell J, Blades KJ, et al. The influence of vitamins and trace element supplements on the stability of the precorneal tear film. Acta Ophthalmol 1993;71:825-9.
46. Blades KJ, Patel S, Aidoo KE. Oral antioxidant therapy for marginal dry eye. Eur J Clin Nutr 2001;55:589-97.
47. Amemiya TS. The eye and nutrition. Jpn J Ophthalmol 2000;44:320.
48. Tseng SCG, Hirst LW, Maumenee AE, et al. Possible mechanisms for the loss of goblet cells in mucin-deficient disorders. Ophthalmology 1984;91:545-52.
49. Paterson AP, O'Rourke MC. Vitamin C levels in human tears. Arch Ophthalmol 1987;105:376-7.
50. Choy CKM, Benzie IFF, Cho P. Ascorbic acid concentration and total antioxidant activity of human tear fluid measured using the FRASC assay. Invest Ophthalmol Vis Sci 2000;41:3293-8.
51. Gogia R, Richer SP, Rose RC. Tear fluid content of electrochemically active components including water soluble antioxidants. Curr Eye Res 1998;17:257-63.
52. Dogru M, Katakami C, Inoue M. Tear function and ocular surface changes in noninsulin-dependent diabetes mellitus. Ophthalmology 2001;108:586-92.
53. Marfurt CF, Echtenkamp SF. The effect of diabetes on neuropeptide content in the rat cornea and iris. Invest Ophthalmol Vis Sci 1995;36:1100-6.
54. Shreeve C. Treating the dry eye. Ophthalmic Optician 1982;25:650-1.
55. Nakamura M, Hikida M, Nakano T, et al. Characterization of water retentive properties of hyaluronan. Cornea 1993;12:433-6.
56. Tsubota K, Yamada M. Tear evaporation from the ocular surface. Invest Ophthalmol Vis Sci 1992;33:2942-50.
57. Golding TR, Baker AT, Rechberger J, et al. X-ray and scanning electron microscopic analysis of the structural composition of tear ferns. Cornea 1994;13:58-66.